Bristol-Myers Squibb ($BMY): Short Setup - Short TermAsset: Bristol-Myers Squibb Co. ( NYSE:BMY ) | Bias: Tactical Bearish |
📌 1. Technical Breakdown & Momentum:
Price Action & EMA Resistance: NYSE:BMY rejected its $68.00–$69.00 highs and is forming lower highs, pushed lower by dynamic resistance at the 20-period EMA.
RSI & Volume
Compare with Bristol-Myers Squibb Company
4.55 USD
7.05 B USD
48.19 B USD
2.04 B
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Christopher S. Boerner
Website
Headquarters
Princeton
Founded
1933
IPO date
Jul 5, 1929
ISIN
US1101221083
CUSIP
110122108
FIGI
BBG000DQLV23
Identifiers
ISIN US1101221083
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Bristol-Myers Squibb Company. BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering medicines across areas including oncology, immunology, cardiovascular disease, and other serious conditions.
From a technical perspective, the chart should be evaluated through the
Bristol Myers Pulls BackBristol-Myers Squibb recently climbed to a three-year high, and now it’s pulled back.
The first pattern on today’s chart is the rally in July and August. The drugmaker is trying to stabilize at a 50 percent retracement of that move, which could suggest it’s trending higher.
Second, BMY made a low
Buying opportunity, clear pullback-Uptrend,
- A breakout from a valid S/R level and pulling back to it.
- Remaining the daily candle, without high shadow over it, could be a good buying opportunity.
- Around 62 can be a good spot for SL and next target will be around 80. unless you feel risk for closing the position.
$BMY | Bristol-Myers Squibb | 1D Technical AnalysisThe chart is showing a constructive recovery after breaking out from a long-term accumulation range. Price is currently consolidating inside a descending channel (bull flag), which is typically considered a continuation pattern following a strong impulsive move.
Technical Structure
The stock succes
This is massiveMassive setup. Potential double bottom and a bullish flag forming to break out the neck. I have calls 57.5 for 12/18/2026. The trade is invalid if the bullish flag gets busted: a weekly candle closes below it. My TP is shown on the chart but a think it can get even higher. This is a keeper.
Bullish potential detected for BMYEntry conditions:
(i) higher share price for NYSE:BMY along with swing up of indicators such as DMI/RSI, and
(ii) observation of market reaction around the potential support/resistance line of $58.61 from the open of 20th May 2024.
Depending on risk tolerance, the stop loss for the trade would be
Bullish ChartReally nice consolidation after the trend break on BMY. Similar names are establishing a nice mini-uptrend.
There is a lot more potential if and when the market starts rotating and/or piling into value/defensive names
Step 1 - truncating the decimal on inflation (today's Fed meeting)
Step 2 - rate
The furniture sector in the UK weak,but Bristol-Myers holds upThe furniture sector in the UK is weak, but Bristol-Myers holds up
Ion Jauregui – Analyst at ActivTrades
The furniture sector in the United Kingdom is weakening due to the slowdown in consumption and the real estate market. The furniture sector in the United Kingdom shows signs of deceleration in
BMY reversal base, range near highs stays constructiveAfter a down phase, BMY built a base that looks like a descending pennant.
The upside breakout flipped structure and released price from the falling framework.
Since the break, price is printing higher highs plus higher lows. That is the new bias.
Price is now in a horizontal bullish consolidatio
See all ideas
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateAug 1, 2097
Coupon6.88% (Fixed)
Maturity dateNov 15, 2063
Coupon6.40% (Fixed)
Maturity dateMar 15, 2062
Coupon3.90% (Fixed)
Maturity dateMar 1, 2044
Coupon4.50% (Fixed)
Maturity dateNov 15, 2053
Coupon6.25% (Fixed)
Maturity dateFeb 22, 2054
Coupon5.55% (Fixed)
Maturity dateMar 15, 2052
Coupon3.70% (Fixed)
Maturity dateNov 15, 2047
Coupon4.35% (Fixed)
Maturity dateFeb 20, 2048
Coupon4.55% (Fixed)
Maturity dateFeb 22, 2064
Coupon5.65% (Fixed)
Maturity dateNov 13, 2050
Coupon2.55% (Fixed)
See all BMY bonds
Frequently asked questions
The current price of BMY is 59.12 USD — it has decreased by −0.77% in the past 24 hours. Watch Bristol-Myers Squibb Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Bristol-Myers Squibb Company stocks are traded under the ticker BMY.
BMY stock has fallen by −2.54% compared to the previous week, the month change is a −8.44% fall, over the last year Bristol-Myers Squibb Company has showed a 31.91% increase.
We've gathered analysts' opinions on Bristol-Myers Squibb Company future price: according to them, BMY price has a max estimate of 82.00 USD and a min estimate of 41.00 USD. Watch BMY chart and read a more detailed Bristol-Myers Squibb Company stock forecast: see what analysts think of Bristol-Myers Squibb Company and suggest that you do with its stocks.
BMY stock is 1.79% volatile and has beta coefficient of 0.12. Track Bristol-Myers Squibb Company stock price on the chart and check out the list of the most volatile stocks — is Bristol-Myers Squibb Company there?
Today Bristol-Myers Squibb Company has the market capitalization of 120.77 B, it has decreased by −4.50% over the last week.
Yes, you can track Bristol-Myers Squibb Company financials in yearly and quarterly reports right on TradingView.
Bristol-Myers Squibb Company is going to release the next earnings report on Oct 29, 2026. Keep track of upcoming events with our Earnings Calendar.
BMY earnings for the last quarter are 2.04 USD per share, whereas the estimation was 1.60 USD resulting in a 27.73% surprise. The estimated earnings for the next quarter are 1.73 USD per share. See more details about Bristol-Myers Squibb Company earnings.
Bristol-Myers Squibb Company revenue for the last quarter amounts to 12.97 B USD, despite the estimated figure of 11.74 B USD. In the next quarter, revenue is expected to reach 12.70 B USD.
BMY net income for the last quarter is 3.32 B USD, while the quarter before that showed 2.68 B USD of net income which accounts for 0.00% change. Track more Bristol-Myers Squibb Company financial stats to get the full picture.
Yes, BMY dividends are paid quarterly. The last dividend per share was 0.63 USD. As of today, Dividend Yield (TTM)% is 4.25%. Tracking Bristol-Myers Squibb Company dividends might help you take more informed decisions.
As of Oct 11, 2026, the company has 32.5 K employees. See our rating of the largest employees — is Bristol-Myers Squibb Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bristol-Myers Squibb Company EBITDA is 19.20 B USD, and current EBITDA margin is 39.92%. See more stats in Bristol-Myers Squibb Company financial statements.
Like other stocks, BMY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bristol-Myers Squibb Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bristol-Myers Squibb Company technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bristol-Myers Squibb Company stock shows the buy signal. See more of Bristol-Myers Squibb Company technicals for a more comprehensive analysis.









